Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk

https://files.fm/u/d7twkx3x23

Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk, and standardization that shape clinical strategy and manufacturing.